Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...